From mesoblast ceo stated below, it is so true and probably apply to the future of resapp.. I am not investor on mesoblast but congrats to their success through fda and rocket shareprice increase !!
And there are big rewards on offer for investors but as Itescu says, the sector also presents significant risks. "Investors should understand that biotech is a highly regulated field — it requires patience, diligence and ultimately you’re in the hands of regulators.“Having said that, there’s got to be more of an understanding of the hurdles but also the rewards, if the tech works and it’s patented and has an exclusive area of focus, really if you can make substantial differences to patients and their outcomes, you have the ability to create a new industry,” Itescu says.
RAP media thread., page-1387
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #